Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
541. |
ECCT/25/07/08 | REACH Heat-stable carbetocin for the treatment of postpartum haemorrhage: a phase III, randomized, double-blind, active controlled, multicountry, multicentre, non-inferiority trial |
Principal Investigator(s) 1. Zahida Qureshi Site(s) in Kenya 1. Machakos county hospital (Machakos county) 2. Pumwani maternity hospital (Nairobi City county) 3. Nakuru Level 5 Hospital (Nakuru county) |
View |
542. |
ECCT/25/08/01 | MK-8527 as HIV-1 PrEP in Women A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women |
Principal Investigator(s) 1. Maricianah Onono Site(s) in Kenya 1. KEMRI-RCTP KISUMU (Kisumu county) 2. Kargeno Research and Policy Hub KEMRI-CMR KISUMU (Kisumu county) 3. KEMRI-PHRD, Thika (Kiambu county) 4. UW KNH - Rachuonyo County Hospital (Homa Bay county) |
View |
543. |
ECCT/25/08/02 | MK-8527-010 A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women. |
Principal Investigator(s) 1. Elizabeth Anne Bukusi Site(s) in Kenya 1. KEMRI CMR RCTP (Kisumu county) |
View |
544. |
ECCT/25/08/03 | Cabotegravir + Rilpivirine Lon A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long acting Combination Therapy Studies |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Aga Khan University Hospital (Nairobi City county) 2. Moi University Clinical Research Centre (Uasin Gishu county) 3. KEMRI-WRP (Kericho county) 4. Kenyatta National Hospital Comprehensive Care Centre (Nairobi City county) |
View |
545. |
ECCT/25/08/04 | MK-8527-010 PrEP A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral MK-8527 Once-Monthly as HIV-1 Preexposure Prophylaxis in Cisgender Women |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya 1. KEMRI-CCR PHRD Thika (Kiambu county) |
View |